Literature DB >> 14697954

Outcomes of liver transplantation for cryptogenic cirrhosis: a single-center study of 71 patients.

A Sanjeevi1, E Lyden, B Sunderman, R Weseman, R Ashwathnarayan, S Mukherjee.   

Abstract

UNLABELLED: Cryptogenic cirrhosis (CC) is emerging as an important indication for orthotoptic liver transplantation (OLT) in the United States. Our aim was to identify risk factors associated with nonalcoholic steatohepatitis (NASH) in patients with CC and to evaluate outcomes following OLT. PATIENTS AND METHODS: A chart review was performed on patients transplanted for CC at the University of Nebraska Medical Center between October 1993 and May 2003.
RESULTS: Seventy-one patients were identified (37 were men and 34 women). Average age was 53.5 years. Mean cholesterol and triglyceride levels increased from 174.8 to 222.3 mg/dL (P <.05) and from 162.60 to 279.66 mg/dL (P <.05), respectively. The prevalence of diabetes mellitus also increased from 37.14% to 54.93% (P <.05). Incidental hepatocellular carcinoma was present in six patients and high-grade dysplasia in one patient. Steatohepatitis developed in eight patients and recurrent cryptogenic disease in four, of whom one required retransplantation for decompensated liver disease. Rejection occurred in 24 patients. Cumulative incidence of graft failure at 1 year was 4% (95% CI 0% to 10%) and at 5 years was 7% (95% CI 0% to 18%). Survival at 1 year was 85% (95% CI 77% to 94%) and at 5 years was 73% (95% CI between 61% to 86%).
CONCLUSIONS: Cryptogenic liver disease is an important cause of decompensated cirrhosis; NASH appears to be an intermediate stage in the development of this disease in a subset of patients. Short-term and 5-year survival rates in this series appear comparable to other liver transplant recipients, supporting liver transplantation as an acceptable treatment for CC.

Entities:  

Mesh:

Year:  2003        PMID: 14697954     DOI: 10.1016/j.transproceed.2003.10.059

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  8 in total

Review 1.  Histopathology of nonalcoholic fatty liver disease.

Authors:  Elizabeth M Brunt; Dina G Tiniakos
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

2.  Indications of Liver Biopsy in the Era of Noninvasive Assessment of Liver Fibrosis.

Authors:  Deepak Amarapurkar; Anjali Amarapurkar
Journal:  J Clin Exp Hepatol       Date:  2015-10-23

3.  Non-cirrhotic portal fibrosis related end stage liver disease in adults: evaluation from a study on living donor liver transplant recipients.

Authors:  Sanjiv Saigal; Nabeen C Nayak; Deepali Jain; Vinay Kumaran; Ravi Mohanka; Neeraj Saraf; Amit Rastogi; Naimesh Mehta; Samiran Nundy; Arvinder Soin
Journal:  Hepatol Int       Date:  2011-01-12       Impact factor: 6.047

Review 4.  Autoantibody-negative autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-12-21       Impact factor: 3.199

Review 5.  Cryptogenic chronic hepatitis and its changing guise in adults.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-06-07       Impact factor: 3.199

6.  Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet.

Authors:  Mary E Rinella; Marc S Elias; Robin R Smolak; Tao Fu; Jayme Borensztajn; Richard M Green
Journal:  J Lipid Res       Date:  2008-01-28       Impact factor: 5.922

Review 7.  Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges.

Authors:  Naga Swetha Samji; Rajanshu Verma; Krishna Chaitanya Keri; Ashwani K Singal; Aijaz Ahmed; Mary Rinella; David Bernstein; Manal F Abdelmalek; Sanjaya K Satapathy
Journal:  Dig Dis Sci       Date:  2019-07-16       Impact factor: 3.199

8.  Liver transplantation for cryptogenic liver failure caused by diffuse hepatic angiosarcoma: case report.

Authors:  Yoshihiro Yoshida; Tomoharu Yoshizumi; Huanlin Wang; Kazuhito Sakata; Masahiro Shimokawa; Takeshi Kurihara; Takashi Motomura; Shinji Itoh; Noboru Harada; Norifumi Harimoto; Toru Ikegami; Hideaki Uchiyama; Yuji Soejima; Yoshihiko Maehara
Journal:  Surg Case Rep       Date:  2017-02-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.